2026 François Ghiringhelli: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	104	603	557	18	18	426	60171
Medicine	104	6905	6494	208	198	445	60251

Overview

François Ghiringhelli is affiliated with Grenoble Alpes University in France and has conducted extensive research primarily in the field of Medicine, with a strong focus on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology, and Surgery. Their scholarly output reflects a multidisciplinary approach to cancer research and related biomedical sciences.

Their work spans several main topics, emphasizing:

Cancer Immunotherapy and Biomarkers
Colorectal Cancer Treatments and Studies
Cancer Genomics and Diagnostics
Immunotherapy and Immune Responses
Lung Cancer Treatments and Mutations
Pancreatic and Hepatic Oncology Research
Gastric Cancer Management and Outcomes

Ghiringhelli has published prolifically in journals such as:

Journal of Clinical Oncology
Annals of Oncology
Cancers
Cancer Research
European Journal of Cancer

A selection of recent publications includes:

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer, 2022, Nature Medicine
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage, 2020, Science
Interleukin-1β and Cancer, 2020, Cancers
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, 2022, JAMA Oncology
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts, 2020, European Journal of Cancer

Frequent collaborators in their research include:

Caroline Truntzer
Valentin Dérangère
Emeric Limagne
Romain Boidot
Christophe Borg

François Ghiringhelli's body of work contributes to advancing understanding in cancer immunotherapy, biomarker identification, and therapeutic strategies across various cancer types including lung, colorectal, pancreatic, and gastric cancers.

Best Publications

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

5342
Citations
Calreticulin exposure dictates the immunogenicity of cancer cell death

Michel Obeid;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;François Ghiringhelli;François Ghiringhelli;François Ghiringhelli;Gian Maria Fimia

3501
Citations
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid

3428
Citations
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

Sophie Viaud;Sophie Viaud;Fabiana Saccheri;Grégoire Mignot;Takahiro Yamazaki

2187
Citations
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

François Ghiringhelli;Lionel Apetoh;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Laetitia Aymeric;Laetitia Aymeric;Laetitia Aymeric

2102
Citations
Immunological aspects of cancer chemotherapy.

Laurence Zitvogel;Lionel Apetoh;Lionel Apetoh;François Ghiringhelli;Guido Kroemer;Guido Kroemer

2021
Citations
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.

Noelia Casares;Marie O. Pequignot;Antoine Tesniere;François Ghiringhelli

1664
Citations
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

François Ghiringhelli;Cedric Menard;Pierre Emmanuel Puig;Sylvain Ladoire

1486
Citations
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Mickaël Michaud;Mickaël Michaud;Mickaël Michaud;Isabelle Martins;Isabelle Martins;Isabelle Martins;Abdul Qader Sukkurwala;Abdul Qader Sukkurwala;Abdul Qader Sukkurwala;Sandy Adjemian;Sandy Adjemian;Sandy Adjemian

1438
Citations
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

Julie Vincent;Grégoire Mignot;Fanny Chalmin;Sylvain Ladoire

1327
Citations
Immunogenic death of colon cancer cells treated with oxaliplatin.

A. Tesniere;F. Schlemmer;F. Schlemmer;F. Schlemmer;V. Boige;O. Kepp;O. Kepp;O. Kepp

1248
Citations
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

Francois Ghiringhelli;Cédric Ménard;Magali Terme;Caroline Flament

1208
Citations
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

François Ghiringhelli;Nicolas Larmonier;Elise Schmitt;Arnaud Parcellier

1151
Citations
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells

Fanny Chalmin;Sylvain Ladoire;Grégoire Mignot;Julie Vincent

1123
Citations
Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation

François Ghiringhelli;Pierre E. Puig;Stephan Roux;Arnaud Parcellier

1011
Citations
Consensus guidelines for the detection of immunogenic cell death

Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli

866
Citations
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

Mélanie Bruchard;Grégoire Mignot;Grégoire Mignot;Valentin Derangère;Valentin Derangère;Fanny Chalmin;Fanny Chalmin

854
Citations
The anticancer immune response: indispensable for therapeutic success?

Laurence Zitvogel;Lionel Apetoh;François Ghiringhelli;Fabrice André

698
Citations
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Alfredo Criollo;Alfredo Criollo;Alfredo Criollo

680
Citations
Classification of current anticancer immunotherapies

Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

584
Citations

Frequent Co-Authors

Lionel Apetoh Indiana University

Guido Kroemer Université Paris Cité

Antoine Tesniere Université Paris Cité

Christophe Borg Centre Hospitalier Universitaire de Besançon

Olivier Bouché CHU de Reims

Julien Taieb Université Paris Cité

Laurence Zitvogel University of Paris-Saclay

Oliver Kepp Institut Gustave Roussy

Valérie Boige Institut Gustave Roussy

Theocharis Panaretakis The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding into healthcare roles can open diverse career pathways. Many professionals pursue advanced nursing qualifications to work closely with immunological treatments and patient care. For instance, a nurse interested in quick advancement may consider a nurse practitioner accelerated program to gain specialized skills efficiently.

Individuals without a nursing background can also enter the field through accessible programs. The best online BSN programs for non nurses offer flexible routes for complete beginners to become registered nurses, complementing Immunology expertise with patient-focused knowledge.

Those seeking quicker entry into nursing may explore accelerated nursing programs, which allow faster onboarding into professional roles. Similarly, the healthcare system values licensed practical nurses (LPNs), and there are easy LPN programs to get into, offering accessible options for immediate hands-on experience.

By aligning studies in Immunology with these nursing pathways, students can build a strong foundation for careers in clinical research, patient care, or public health, maximizing impact in the evolving medical landscape.